BPGbio moves closer to Phase 3 in rare mitochondrial disease

New findings suggest investigational therapy may overcome a longstanding challenge in treating primary CoQ10 deficiency. In drug development, sometimes, the biggest story is what regulators are willing to do with the evidence. AI-powered, clinical-stage biopharma company BPGbio has revealed new findings supporting BPM31510, its investigational therapy for primary CoQ10 deficiency (PCQD), while revealing something equally […] The post BPGbio moves closer to Phase 3 in rare mitochondrial disease appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.